Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
1. Jeito Capital participates significantly in Odyssey's $213M Series D financing. 2. Investment supports Odyssey's development of medicines for autoimmune diseases. 3. Odyssey’s lead compound targets chronic inflammatory bowel diseases. 4. Jeito's expertise enhances Odyssey's ability in immunology and inflammation. 5. Investment reflects high demand for innovative therapies in autoimmune conditions.